Abstract
Since the discovery of tumor necrosis factor (TNF)-alpha, researchers have pursued many approaches to harness the potency of TNF-alpha and TNF superfamily members to treat human cancers. Several ligands of the TNF superfamily, including TNF-alpha, lymphotoxin, FAS ligand (FasL), and APO2 ligand/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) have been tested in various stages of clinical research for their anti-tumor efficacy. Moreover, several antibodies to TNF receptor (TNFR) superfamily members are now being explored as cancer therapeutics. Due to the toxicity associated with delivering TNF-alpha systemically at clinically relevant doses, more targeted methods are now seen as a likely alternative to provide a localized therapeutically effective dose of TNF-alpha. In this review we revisit historical attempts to use TNF-alpha to treat human cancer, and put this into the context of more recent targeted strategies to circumvent TNF-alphas systemic toxicity. We will attempt to integrate the results of pre-clinical and clinical trials with a concise synopsis of the TNF-alpha signaling network, with the goal of reconciling our understanding of how the cell biology and tumor biology mechanistically relate.
Current Cancer Drug Targets
Title: Tumor Necrosis Factor: Renaissance as a Cancer Therapeutic?
Volume: 8 Issue: 2
Author(s): D. Daniel and N. S. Wilson
Affiliation:
Abstract: Since the discovery of tumor necrosis factor (TNF)-alpha, researchers have pursued many approaches to harness the potency of TNF-alpha and TNF superfamily members to treat human cancers. Several ligands of the TNF superfamily, including TNF-alpha, lymphotoxin, FAS ligand (FasL), and APO2 ligand/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) have been tested in various stages of clinical research for their anti-tumor efficacy. Moreover, several antibodies to TNF receptor (TNFR) superfamily members are now being explored as cancer therapeutics. Due to the toxicity associated with delivering TNF-alpha systemically at clinically relevant doses, more targeted methods are now seen as a likely alternative to provide a localized therapeutically effective dose of TNF-alpha. In this review we revisit historical attempts to use TNF-alpha to treat human cancer, and put this into the context of more recent targeted strategies to circumvent TNF-alphas systemic toxicity. We will attempt to integrate the results of pre-clinical and clinical trials with a concise synopsis of the TNF-alpha signaling network, with the goal of reconciling our understanding of how the cell biology and tumor biology mechanistically relate.
Export Options
About this article
Cite this article as:
Daniel D. and Wilson S. N., Tumor Necrosis Factor: Renaissance as a Cancer Therapeutic?, Current Cancer Drug Targets 2008; 8 (2) . https://dx.doi.org/10.2174/156800908783769346
DOI https://dx.doi.org/10.2174/156800908783769346 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Topical Fluoride for Preventing Dental Caries in Children and Adolescents
Current Pharmaceutical Design Resistant Hypertension in the Elderly-Second Line Treatments: Aldosterone Antagonists, Central Alpha-Agonist Agents, Alpha-Adrenergic Receptor Blockers, Direct Vasodilators, and Exogenous Nitric Oxide Donors
Cardiovascular & Hematological Agents in Medicinal Chemistry Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach
Current Medicinal Chemistry Promising Protective Effects of Chrysin in Cardiometabolic Diseases
Current Drug Targets Antidiabetic Potential of Fabaceae Family: An Overview
Current Nutrition & Food Science The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews Induction of Cytochrome P450 3A by the Ginkgo biloba Extract and Bilobalides in Human and Rat Primary Hepatocytes
Drug Metabolism Letters Thrombocytopenia in HIV Disease: Clinical Relevance, Physiopathology and Management
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Current Metabolomic Methodologies & their Application to Thermal Stress
Current Metabolomics Intrathecal Apelin-13 Produced Different Actions in Formalin Test and Tail-flick Test in Mice
Protein & Peptide Letters Risk Factors and Potential Preventive Measures for Vascular Disease Progression in Hemodialysis Patients
Vascular Disease Prevention (Discontinued) Detection and Treatment of Alcohol-Induced Hypertension
Current Hypertension Reviews Fatal Disseminated Toxoplasmosis During Primary HIV Infection
Current HIV Research Drug Treatment of Metabolic Syndrome
Current Clinical Pharmacology Synthesis of 5-Arylidene Barbiturates: A Novel Class of DPPH Radical Scavengers
Letters in Drug Design & Discovery Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
Current Cancer Therapy Reviews Adrenomedullin in Hypertension
Current Hypertension Reviews Drugs and Aggression
Recent Patents on CNS Drug Discovery (Discontinued) Effects of Antiplatelet Medication on Arteriovenous Fistula Patency After Surgical Thrombectomy
Current Vascular Pharmacology Permeating the Blood Brain Barrier and Abrogating the Inflammation in Stroke: Implications for Stroke Therapy
Current Pharmaceutical Design